Inhibition of multiple voltage-gated calcium channels may contribute to spinally mediated analgesia by epipregnanolone in a rat model of surgical paw incision

Sonja Lj. Joksimovic a, Rebecca R. Donald b, Ji-Yong Park c, and Slobodan M. Todorovic a,d

 aDepartment of Anesthesiology, University of Colorado Denver, Aurora, CO, USA; bDepartment of Anesthesiology, Duke University Medical School, Durham, NC, USA; cDepartment of Anesthesiology and Pain Medicine, College of Medicine, Korea University, Seoul, Republic of Korea; dNeuroscience Graduate Program, University of Colorado Denver, Aurora, CO, USA

ABSTRACT

Voltage-activated calcium channels play an important role in excitability of sensory nociceptive neurons in acute and chronic pain models. We have previously shown that low-voltage-activated calcium channels, or T-type channels (T-channels), increase excitability of sensory neurons after surgical incision in rats. We have also found that endogenous 5β-reduced neuroactive steroid epipregnanolone [(3β,5β)-3-hydroxypregnan-20-one] blocked isolated T-currents in dorsal root ganglion (DRG) cells in vitro, and reduced nociceptive behavior in vivo, after local intraplantar application into the foot pads of healthy rats and mice. Here, we investigated if epipregnanolone exerts an antinociceptive effect after intrathecal (i.t.) application in healthy rats, as well as an antihyperalgesic effect in a postsurgical pain model. We also studied if this endogenous neurosteroid blocks originating from high voltage-activated (HVA) calcium channels in rat sensory neurons. In in vivo studies, we found that epipregnanolone alleviated thermal and mechanical nociception in healthy rats after i.t. administration without affecting their sensory-motor abilities. Furthermore, epipregnanolone effectively reduced mechanical hyperalgesia after i.t. application in rats after surgery. In subsequent in vitro studies, we found that epipregnanolone blocked isolated HVA currents in nociceptive sensory neurons with an IC50 of 3.3 μM in a G-protein-dependent fashion. We conclude that neurosteroids that have combined inhibitory effects on T-type and HVA calcium currents may be suitable for development of novel pain therapies during the perioperative period.

Introduction

Despite the fact that numerous life-saving surgical procedures are performed on a daily basis, treatment of pain arising after surgery continues to be an underestimated problem in patients. One of the reasons is suboptimal clinical pain management, which often leads to the development of chronic pain after surgery [1,2]. Opiate analgesics are commonly prescribed medicines for the treatment of post-operative pain, even though their application is often followed by a plethora of adverse events, complicating post-surgical outcomes and patient recovery [3,4]. Therefore, there is an increased recognition of the need to improve our scientific and clinical knowledge in the field of post-operative pain management and investigate novel treatments for alleviating pain with fewer adverse events.

Several subtypes of voltage-gated calcium channels (VGCCs) are expressed in neurons in the pain pathways, and are crucial not only in shaping action potentials, but also in controlling cellular excitability and synaptic transmission in these cells. On the basis of the membrane potential at which they become activated, VGCCs are subdivided into two major classes: high-voltage-activated (HVA) or sustained currents; and low-voltage-activated (LVA) or transient (T-type) currents [5]. These channels are products of different genes that encode α1 subunits, which form the pores of the VGCCs. The genes can be grouped into families based on α1 subunits: Cav1 (former α1S, α1C, α1D, α1F) encoding L-type channels; Cav2.1 (α1A) encoding P/Q-type channels; Cav2.2 (α1B) encoding N-type channels; and Cav2.3 (α1E) encoding R-type channels, which activate at more negative potentials than other HVA channels.
The supportive role of T-channels in pain pathways has been relatively well established. Consistent with this notion, blocking peripheral T-channels leads to a very potent antinociceptive effect in models of somatic [6–9] and visceral pain [10]. Also along these lines, we reported recently that upregulation of the CaV3.2 isoform of T-channels in DRG sensory neurons supports the development and maintenance of hyperalgesia after surgical incision [11]. Several other studies have investigated the role of HVA calcium channels in postsurgical pain models. Wang and colleagues applied ziconotide, an N-type calcium channel blocker, intrathecally after skin incision, and this alleviated thermal hyperalgesia in a dose-dependent manner [12]. In addition, Field et al. [13] demonstrated preventative application of gabapentin, a ligand for the α2δ ancillary subunits of VGCCs, relieved postsurgical thermal hyperalgesia and tactile allodynia in incised rats.

An increasing body of evidence suggests that endogenous neurosteroids and their synthetic analogues have significant potential as analgesics [14]. Recent studies have confirmed the production of neurosteroids in the spinal cord, a pivotal part of the central nervous system for transmission of information regarding painful stimuli from the periphery [15–17]. Neurosteroids exert their various effects on the sensory transmission by modulating numerous receptor-operated systems (GABA_A, NMDA, nuclear receptors) and various VGCCs [18–21]. Several studies have implicated endogenous neurosteroids, such as pregnane and its derivatives, in the prevention of allodynia in neuropathic pain, as well as mechanical and thermal hyperalgesia in an inflammatory pain model in rats [17,22,23]. Our previous study showed that 5α-reduced neurosteroids exert their analgesic effects mostly by interacting with GABA_A receptors and T-channels in peripheral nociceptive neurons [24]. We have also shown that in rat and mouse dorsal root ganglia (DRG) sensory neurons, the endogenous 5β-reduced neurosteroid epipregnanolone [(3β,5β)-3-hydroxy pregnan-20-one] (Figure 1) exerts potent analgesia in healthy rats and mice as a result of inhibition of the CaV3.2 isoform of T-channels, without having an effect on GABA_A-mediated currents [25]. We have also found that that the ability of synthetic 5β-reduced neurosteroids to produce an antinociceptive effect in healthy rats correlates well with their potency in blocking CaV3.2 channels in rat DRG sensory neurons [26].

In this study, we investigated analgesic properties of epipregnanolone on surgically induced hyperalgesia using a plantar incision of the hind paw in rats [27], which is a rodent model considered to be similar in context to the underlying mechanisms and the development of human postsurgical pain [28]. Given the importance of multiple subtypes of VGCCs in pain transmission, this study also examined the effects of epipregnanolone on isolated HVA calcium currents in nociceptive sensory neurons in the DRG.

**Materials and methods**

**Animals**

All *in vivo* experiments were performed with young female Sprague-Dawley rats (P25-P70; Envigo, Indianapolis, IN, USA). Animals were housed two per cage and maintained on a 12 h light-dark cycle with access to food and water *ad libitum*. Experimental protocols were in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996), and were approved by the Animal Care and Use Committee of the University of Colorado Anschutz Medical Campus and the University of Virginia.
Drugs

Epipregnanolone \([(3\beta,5\beta)-3\text{-hydroxypregnan-20-one}]\) is an endogenously produced neurosteroid that we obtained from Steraloids, Inc. (Newport, RI). For intrathecal (i.t.) injections, the compound was dissolved in a solution of 15% 2-Hydroxypropyl-\(\beta\)-cyclodextrin in pH-balanced saline (pH = 7.4 to avoid tissue irritation). 2-Hydroxypropyl-\(\beta\)-cyclodextrin (45% solution) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Incisional pain model

In order to study the antihyperalgesic effect of epipregnanolone after surgery, we used a skin and muscle incision for the induction of postsurgical pain [27]. Animals were anesthetized with isoflurane (2.5% for induction and for maintenance) and the plantar surface of the right paw was incised longitudinally with a No.11 surgical blade. The underlying plantaris muscle was elevated and also incised longitudinally, after which the skin was sutured with 5–0 nylon suture using an FS-2 needle. Animals were allowed to recover in cages, and all experiments were initiated as early as 24 h post-incision.

Intrathecal injections

After briefly anesthetizing animals with isoflurane (2.5% for induction in an induction chamber, and 2.5% for maintenance), the back of each animal was shaved to expose the injection site in the L\(_4\)-L\(_6\) region of the spinal column. A 28 G needle was used for the acute i.t. injection. After inserting the needle into the L\(_4\)-L\(_6\) lumbar region, the experimental compound or vehicle was delivered in a volume of 50 µl, and the animal was left to recover in a cage before initiating experiments.

Thermal nociception testing

For assessment of thermal (heat) nociception threshold, experiments were performed as previously described [11]. In brief, after 15 minutes of acclimation, a radiant heat source is positioned directly underneath a plantar surface of the hind paws to deliver a thermal stimulus and an automatic timer begins. When the animal withdrew the paw, the automatic timer shut off, therefore measuring the animal’s paw withdrawal latency (PWL). To prevent thermal injury, the light beam was automatically discontinued at 20 s, if the rat failed to withdraw its paw. For this study, each paw was tested three times and the average value of the PWLs was used in further analysis.

Mechanical sensitivity

In order to determine mechanical sensitivity in rats, we used the electronic Von Frey apparatus (Ugo Basile, Varese, Italy) as previously described [11]. In brief, after habituation of the animals in plastic enclosures, a rigid metal probe was applied to the plantar surface of the paw through the mesh floor of the stand, and constant force, in a range of 0–50 g, was applied to the mid-plantar area of the paw. As soon as the exerted pressure of the punctate stimulus reached the maximum force that the animal can endure, immediate brisk paw withdrawal was noticeable, and the force in grams was displayed on the apparatus representing a threshold for paw withdrawal response (PWR). In this study, each paw was tested three times and the average value of threshold PWRs was used in further analysis. Any other voluntary movement of the animal was not considered as a response.

Assessment of sensorimotor abilities

To eliminate the possible effect of the highest applied dose of the tested drug on sensorimotor abilities [29], we tested unoperated rats before and after an i.t. injection of 300 µM epipregnanolone. Animals were tested on four different sensorimotor tasks: ledge, walking initiation, elevated platform, and inclined plane. Ledge experiments measured the number of seconds the rat remained on a 3 cm-wide plank. Means for each animal were calculated over two trials, with a maximum of 60 seconds per trial. Walking initiation experiments were conducted by placing a rat in the center of a 50 cm x 50 cm square made with pieces of tape on a desk. Time was measured as the number of seconds necessary for the rat to move all four paws off the square. For elevated platform experiments, a rat was placed on a platform (7.6 x 15.2 cm) positioned 61 cm above the ground. Time was measured by the number of seconds the animal could remain on the platform. A mean value was calculated from two trials with a maximum of 120
seconds (test cut-off value). For inclined plane experiments, the rat was placed in the middle of a wire mesh screen (8 squares in 10 cm) tilted at a 60° angle with head facing down. Time was measured by the number of seconds the rat could remain on the inclined screen before falling off. The cut-off value was 120 seconds, which was assumed to be the maximum time an animal could remain on the inclined screen.

**Tissue preparation for electrophysiological recordings**

Dissociated cell bodies from neurons of the dorsal root ganglion (DRG) were harvested from adolescent rats of both sexes and prepared as we previously described [11]. Briefly, after anesthetizing the animals with 5% isoflurane, and decapitating with a guillotine, DRGs were removed and immediately placed in ice-cold Tyrode's solution, containing 140 mM NaCl, 4 mM KCl, 2 mM MgCl₂, 10 mM glucose, and 10 mM Hepes, adjusted to pH 7.4 with NaOH. After harvesting, the tissue was transferred into Tyrode's solution containing collagenase H (Sigma-Aldrich) and dispase II (Roche) and incubated for 50 min at 35°C. Dissociated single neuronal cell bodies were obtained by trituration in Tyrode's solution at room temperature through fire-polished pipettes of progressively reduced sized tips. After trituration, cells were plated onto uncoated glass coverslips, placed in a culture dish, and perfused with external solution. All in vitro experiments were done at room temperature. Only small-sized DRG cells with a soma diameter < 30 μm were used in recordings. All recordings used in this study were obtained from a total of 51 DRG cells from 28 rats with an average soma diameter of 22.9 ± 4.1 μm.

**Electrophysiological methods**

Recordings were made with standard whole-cell, voltage-clamp techniques previously described [11]. Pipette resistances were 2 to 5 MΩ. Reported series resistance and capacitance values were taken from the reading of the amplifier. Typically cells were held at −50 mV and depolarized to −10 mV every 20 seconds to evoke inward currents. Data were analyzed using Clampfit 10.4 (Axon Instruments, Foster City, CA) and Origin 7 (Microcal Software, Northhampton, MA). Currents were filtered at 5 kHz. All experiments were done at room temperature (20–23°C). In most experiments, leakage subtraction was used with a P/5 protocol for on-line leakage subtraction.

The external solution for electrophysiology recordings of Ca²⁺ currents in DRG cells contained: 160 mM TEA-Cl, 10 mM HEPES, 5 to 10 mM BaCl₂, adjusted to pH 7.4 with TEA-OH; osmolarity, 316 mOsM. Cells were generally maintained in a Tyrode’s solution until seal formation, at which time the bath solution was switched to the Ba²⁺ saline. The internal solution consisted of 110 mM Cs-methane sulfonate, 14 mM phosphocreatine, 10 mM HEPES, 9 mM EGTA, 5 mM Mg-ATP, and 0.3 mM tris-GTP, pH adjusted to 7.15 to 7.20 with CsOH (standard osmolarity, 300 mOsM). In some experiments, GTP in the internal solution was preplaced with its inactive analogs 100 μM GTP-γ-S or 2 mM GDP-β-S in order to investigate the role of G-proteins in inhibition of HVA calcium currents. Another method to interrogate the role of G-proteins involves strong, brief depolarization (e.g. +100 mV), which would be expected to relieve G-protein-mediated inhibition of HVA calcium currents [30]. We have not performed such experiments with strong depolarizing prepulse relief in our acute preparation of DRG cells because of difficulties in keeping stable whole-cell recordings following extremely positive membrane potentials.

**Data analysis and statistics**

Each data point from behavioral experiments was expressed as mean ± SEM. The differences in effects between the treatment and the vehicle groups was performed using two-way repeated measures analysis of variance (RM-ANOVA) followed by Sidak’s post-hoc test, and paired t-test. Significant differences between group means are indicated when p < 0.05. GraphPad Prism 7 was used for all statistical analyses. Origin 7 was used to calculate ED₅₀.

For the concentration-response curve of epi-pregnanolone inhibition of calcium currents, all points are averages of multiple determinations obtained from at least 3 different cells. All concentrations were applied to the cells until an apparent steady state effect was achieved. On all plots, vertical bars indicate standard errors. Mean values on
concentration-response curves were fit to the Hill-Langmuir function: 

\[ \text{PB}(\text{Epipregnanolone}) = \frac{\text{PB}_{\text{max}}}{1 + (\text{IC}_{50}/\text{Epipregnanolone})^n} \]

where \( \text{PB}_{\text{max}} \) is the maximal percent block of peak current, the \( \text{IC}_{50} \) is the concentration that produces 50% of maximal inhibition, and \( n \) is the apparent Hill coefficient for blockade. Fitted values are typically reported with 95% linear confidence limits.

**Results**

**Antinociceptive effects of intrathecally administered epipregnanolone on thermal and mechanical nociception in healthy rats**

Our previous study demonstrated that when injected into peripheral receptive fields of a rat’s paw, epipregnanolone exerted a potent antinociceptive effect on a thermal nociceptive stimulus [25]. Here, we examined if local intrathecal (i.t) application of epipregnanolone could alleviate thermal and mechanical nociception in healthy rats. Animals were injected i.t. with epipregnanolone and nociceptive measurements began 30 minutes post-injection (Figure 2(a)). Indeed, epipregnanolone exerted a substantial dose-dependent antinociceptive effect to a thermal stimulus during 150 minutes post i.t. injection as indicated by a transient increase in the thermal PWLs up to 45% when compared to pre-injection baselines. The peak effect was observed 30 minutes after injection (Figure 2(b)). The compound was tested at three concentrations (3, 100 and 300 µM) each applied in a volume of 50 µl. While the concentrations of 100 and 300 µM, each applied in a volume of 50 µl, exerted a prominent antinociceptive effect, the lowest concentration of 3 µM, in a volume of 50 µl, did not offer any significant alleviation of nociceptive behavior in thermal nociceptive testing. In order to investigate the effects of epipregnanolone on mechanical nociception, we used the highest effective concentration of epipregnanolone from the previous experiments with thermal nociception (Figure 2(b)). As expected, 300 µM epipregnanolone, applied in a volume of 50 µl, markedly reduced responsiveness to mechanical stimulus after i.t. application in healthy rats (Figure 2(c)), as indicated by an increase in the average PWLRs of about 30% which persisted for 90 minutes. The effect of epipregnanolone on mechanical nociception was longer lasting than for thermal nociception (compare Figures 2(b, c)).

**Effect of epipregnanolone on sensory-motor abilities of the injected healthy rats**

Responsiveness to painful stimuli could be reduced if injection of epipregnanolone interferes with the motor capabilities of animals. Therefore, we tested the sensorimotor abilities of healthy rats before and 30 minutes after neuropeptide injection (Figure 3(a)). Sensorimotor performance on the plank (Figure 3(b)), walking initiation (Figure 3(c)), elevated platform (Figure 3(d)) or inclined screen (Figure 3(e)) did not differ significantly before or after an i.t. injection of 300 µM epipregnanolone, applied in a volume of 50 µl. Although the time needed to walk out of the designated square on the walking initiation task was shorter post-injection compared to pre-injection, the difference in time was not statistically significant. Hence, we concluded that any decrease in response to painful stimuli after injections of epipregnanolone would not be a consequence of motor impairment.

**Effects of single intrathecal application of epipregnanolone on post-incision hyperalgesia in rats**

To determine if epipregnanolone alleviates post-surgical hypersensitivity, we injected rats i.t. with either 50 µl of 300 µM epipregnanolone or vehicle at the time point of 24 h after a surgical incision and measured the response to a mechanical stimulus over a period of 120 minutes post-injection (Figure 4(a)). We chose to perform our experiments 24 h after surgery, because previous study had shown that hyperalgesia is fully developed at 24 and 48 h after surgery [11]. Our experiments in healthy rats showed that an injection of 50 µl of 300 µM epipregnanolone exerted the most prominent antinociceptive effect (Figure 2(c)). Hence, we used this concentration in our experiments with post-surgical pain model. We found that
a single i.t. injection of 50 µl of 300 µM epipregnanolone effectively alleviated mechanical hyperalgesia as evidenced by a lasting increase in PWRs of about 2-fold when compared to the pre-injection baselines (Figure 4(b)). Importantly, the antihyperalgesic response to a mechanical punctate stimulus was significantly greater than vehicle injected rats over the entire period of 120 minutes post-injection (p = 0.0038).
the P-type [32], Q-type [33], and a component unblocked by any known blocker [33], presumably R-type. Furthermore, it is generally accepted that that the majority of small size DRG neurons are nociceptors. Therefore, for examination of the effects of epipregnanolone on HVA currents in DRG neurons, we selected only smaller-diameter cells.

In order to investigate if antihyperalgesic effects of epipregnanolone might, at least in part, be due to its inhibitory effects on HVA calcium channels, we compared the amplitudes of evoked calcium currents in the same DRG neurons in the control conditions before drug applications, and in the presence of 10 µM epipregnanolone. Indeed, we found that 10 µM epipregnanolone effectively suppresses evoked calcium currents.

Figure 3. Intrathecal application of epipregnanolone does not impair sensory-motor abilities of rats. (a). Schematic representation of experimental protocol for baseline measures of sensorimotor abilities prior to injection, and assessment performed after an intrathecal injection (i.t.) of 50 µl of 300 µM epipregnanolone. (b). Bar graph demonstrates time rats remained on the plank before and after an i.t. injection of 50 µl of 300 µM epipregnanolone (n = 6 rats for each group). (c). Bar graph of walking initiation demonstrates time required for rats to place all four paws outside the labeled square before and after i.t. injection of 50 µl of 300 µM epipregnanolone (n = 6 rats for each group, paired t-test, p = 0.21). (d). Bar graph demonstrates time rats remained on elevated platform before and after i.t. injection of 50 µl of 300 µM epipregnanolone (n = 6 rats for each group) (e). Bar graph demonstrates time rats remained on inclined screen before and after i.t. injection of 50 µl of 300 µM epipregnanolone (n = 6 rats for each group).
reduced peak HVA currents (Figure 5(a)) compared to control baseline currents in the same cells. Washout of epipregnanolone resulted in a return of HVA currents close to pretreatment levels (Figure 5(a)), demonstrating the block was reversible. Furthermore, epipregnanolone inhibited HVA currents in a concentration-dependent manner, with an $IC_{50}$ of 3.3 µM; an 85% maximal block indicated nearly complete inhibition (Figure 5(b)). Next, in order to study the mechanisms of the interaction between HVA calcium channels and epipregnanolone, we examined whether G-proteins could be involved in the inhibition of HVA currents in DRG neurons by adding known activators and inhibitors of G proteins to the internal recording solution (Figure 5(c)). Under control conditions of recording the effects of epipregnanolone in the presence of GTP, approximately 70% inhibition of HVA currents occurred in DRG neurons (Figure 5(c), red bar). In the next set of experiments activation of G-proteins was achieved by adding 100 µM GTP-$\gamma$-S to the recording solution; GTP-$\gamma$-S activates G-proteins persistently and prevents subsequent effects of G-protein-dependent agonists. A significant reduction of the epipregnanolone-induced inhibition of HVA (p < .001) occurred in the presence of GTP-$\gamma$-S (Figure 5(c), white bar). To validate this finding in

![Figure 4. Single intrathecal application of epipregnanolone reduces mechanical nociception in incised rats. (a). Schematic representation of protocol. Baseline measurements of paw withdrawal response (PWR) following mechanical stimulus determined two days before the incision, and assessment post-injection in surgically incised rats. Intrathecal (i.t.) injections of vehicle or 300µM epipregnanolone, each applied in a volume of 50 µl, were performed 24 h post-incision followed by assessment of mechanical hyperalgesia at 30, 60, 90 and 120 minutes post-injection. (b). Graph of time-course for PWR following i.t. injection of vehicle or 300µM epipregnanolone, each applied in a volume of 50 µl, showing antihyperalgesic effect of epipregnanolone on mechanical nociception (n = 4–7 rats per group, two-way RM ANOVA, interaction: p = 0.61; treatment: F(1,9) = 15.01, ** p = 0.0038). Each data point represents the mean ± SEM.

![CHANNELS 55]
another set of independent experiments, inhibition of G-protein–mediated signaling was next achieved by introducing 2 mM GDP-β-S, an antagonist of G-protein activation into the recording pipette \[34\]. Similar to GTP-γ-S, we found that GDP-β-S significantly diminished epipregnanolone-induced inhibition of HVA currents in DRG cells (p < .001) to approximately 50% of control response (Figure 5(c), gray bar).

These results are consistent with a notion that HVA current reduction occurring after epipregnanolone application is most likely G-protein dependent.

Discussion

To our knowledge, this is the first study investigating the analgesic potential of an endogenous neurosteroid in an acute somatic postsurgical pain model. The discovery of endogenous neurosteroids present in the spinal cord, as well as the enzymes involved in steroidogenesis at both spinal and supraspinal levels \[35\], is strongly suggestive of their involvement in modulation of pain transmission \[16,36\]. It is already established that endogenously produced 5α-reduced derivatives of progesterone, such as allopregnanolone and
dihydroprogesterone, exert antihyperalgesic effects in neuropathic and inflammatory pain models [17,24,37-41]. Epipregnanolone belongs to the group of 5β-reduced endogenous neurosteroids derived from progesterone by the actions of 5β-reductase and 3β-hydroxysteroid dehydrogenase. We have previously shown that local intraplantar application of epipregnanolone reduced both thermal and mechanical nociception in the wild type mice, but was ineffective in CaV3.2 knock-out mice [25].

Our in vivo methods demonstrated that epipregnanolone exerts an antinociceptive effect after i.t. application in healthy rats and an effective antihyperalgesic effect in a postsurgical pain model. An i.t. application of epipregnanolone was employed in our studies because it represents a common route of administration of analgesics in clinical practice [42]. Indeed, an i.t. application of epipregnanolone alleviated thermal nociception in healthy rats in a dose-dependent manner. Importantly, we demonstrated that an i.t. application of 50 µl of 300 µM epipregnanolone, the highest effective concentration, did not interfere with sensorimotor function of healthy rats. Additionally, the same concentration of epipregnanolone applied intrathecally in healthy rats also reduced mechanical sensitivity. Finally, in surgically incised rats, an i.t. injection of 50 µl of 300 µM epipregnanolone on postsurgical day 1 effectively attenuated mechanical hyperalgesia.

Previous studies have reported that non-NMDA [43,44] and opioid receptors [45] are involved in the maintenance of incisional pain, however the exact mechanisms and mediators involved in the development of incisional pain have not been determined. It is well established that VGCCs (particularly T-type and N-type) contribute to the transmission of nociceptive signals in primary afferent fibers [46,47]. In addition, we know the CaV3.2 T-channel isoform is present on the cell bodies of peripheral nociceptive neurons in the DRG [48,49], and on the presynaptic terminals in laminae I and II of the dorsal horn of the spinal cord, thus facilitating excitatory neurotransmission [50]. We recently demonstrated an increase in current density of T-channels on the cell bodies of DRG sensory neurons in a surgical incision pain model [11]. In addition, we previously found that epipregnanolone exerts antinociceptive effects in healthy rats, in part by reversibly blocking T-channels in peripheral DRG neurons with an IC50 of 3 µM [25]. In the same study, we reported that epipregnanolone did not have any effect on sodium, potassium and gamma-aminobutyric acid (GABA)-gated ionic currents in DRG neurons. We continue here by showing that epipregnanolone inhibits HVA calcium currents in nociceptive DRG neurons with similar potency as reported for T-currents. Collectively, these findings suggest that antihyperalgesic effect of epipregnanolone in the postsurgical pain model may be mediated in concert via inhibition of T-channels and HVA channels in nociceptors.

It is also important to speculate on the nature of HVA calcium current in DRG neurons that are inhibited by epipregnanolone. It is clear that the transduction and processing of pain signals are dependent on, and modulated by, various ion channels and receptors [51]. Therefore, besides T-channels, N-type (CaV2.2) VGCCs emerge as possible targets involved in modulation of pain perception and transmission of pain signals. The N-type channel consists of α1B- (CaV2.2), β-, and α2δ-subunits forming a hetero-oligomer [52]. They are expressed only in neuronal tissue, with particularly high levels of expression in the lamina I and II of the dorsal horn, which represent a main pain-processing region of the spinal cord. It has been reported that blocking N-type channels prevents the release of neuropeptides from primary afferents in the dorsal horn such as substance P [53]. Furthermore, inhibition of trafficking of the CaV2.2 channel reduces inflammatory and postsurgical pain [54]. Lastly, mutant mice lacking the gene that encodes the N-type channel exhibit less sensitivity in neuropathic and inflammatory pain models, when compared with wild type mice [55,56].

Field and colleagues [13] demonstrated that gabapentin administered subcutaneously reduced thermal and mechanical hyperalgesia in a postsurgical pain model in rats. Gabapentin exerts its effect likely by binding to the αδ-subunit of VGCCs, therefore these findings also suggest a possible involvement of HVA calcium channels in the development of postsurgical pain. Next, Wang and colleagues [12] reported that an i.
t. bolus injection of ziconotide, an N-type calcium channel blocker, applied after surgery, significantly reduced mechanical and thermal hyperalgesia in incised paws. Furthermore, in the same study, a preemptive i.t. injection of ziconotide reduced both thermal hyperalgesia and mechanical allodynia post-incision. Importantly, clinical trials demonstrated that i.t. ziconotide significantly relieved postsurgical pain in patients, and also reduced morphine consumption [57]. These previous studies strongly implicate N-type HVA calcium channels in the development of postsurgical pain, which prompted us to investigate whether epipregnanolone could block HVA currents in putative nociceptive DRG neurons.

Our in vitro studies showed epipregnanolone reduced the amplitudes of HVA currents (mainly N-type and L-type) in putative nociceptors in a concentration-dependent manner. We also demonstrated that GTP-γ-S and GDP-β-S diminished the ability of 10 µM epipregnanolone to block HVA currents, indicating the reduction in HVA currents was G-protein dependent. Other neurosteroids have been reported to produce inhibitory effects on HVA currents in hippocampal neurons [58], as well as acutely dissociated DRG cells [59]. Importantly, by effectively preventing G-protein coupled modulation, GDP-β-S and GTP-γ-S have been shown to indirectly modulate N-type, but not L-type HVA currents in small DRG cells [59]. Furthermore, previous studies have firmly established the role of G-protein regulation of N-type calcium currents in nociceptive DRG neurons [60–62]. Our data strongly suggest that G-protein-dependent inhibition of HVA currents in small DRG neurons is due to epipregnanolone inhibition of N-type currents. L-type calcium channels have also been implicated in nociception. Although pharmacological studies have suggested analgesic potency of traditional L-type blockers [63–65], the role of L-type VGCCs in post-surgical hyperalgesia was not well studied. It has been demonstrated that systemically applied blockers of L-type calcium channels potentiate antinociceptive effect of morphine and other opiate derivatives [66,67]. However, intrathecal application of verapamil, a potent L-type calcium channel blocker, did not show antinociceptive effect in the tail-flick test in rats [68]. Future studies are necessary to assess the involvement of L-type VGCCs in incisional pain development and spinally mediated analgesia post surgery.

Our findings demonstrate that epipregnanolone, an endogenous neurosteroid, can effectively reduce postsurgical hyperalgesia in rats, most likely by targeting the CaV3.2 isoform of T-type calcium channels and N-type HVA calcium channels in nociceptors. Furthermore, our data strongly suggest that the effect of epipregnanolone on HVA calcium channels is, at least in part, mediated via G-protein dependent signaling pathways. These data show that neurosteroids that have combined inhibitory effects on T-type and HVA calcium currents may be suitable for development of novel pain therapies in the perioperative period.

Disclosure statement
No potential conflict of interest was reported by the authors.

Funding
Supported by NIH grant 1 R01 GM123746-01 to SMT, the funds from the Department of Anesthesiology at UC Anschutz Medical Campus and the University of Virginia, Charlottesville, National Institute of General Medical Sciences [R01 GM123746-01].

ORCID
Sonja Lj. Joksimovic http://orcid.org/0000-0001-9280-162X
Slobodan M. Todorovic http://orcid.org/0000-0003-2613-0391

References
[1] Chapman CR, Stevens DA, Lipman AG. Quality of postoperative pain management in American versus European institutions. J Pain Palliat Care Pharmacother. 2013 Dec;27(4):350–358.
[2] Gerbershagen HJ, Pogatzki-Zahn E, Aduckathil S, et al. Procedure-specific risk factor analysis for the development of severe postoperative pain. Anesthesiology. 2014 May;120(5):1237–1245.
[3] Apfelbaum JL, Chen C, Mehta SS, et al. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged.
Anesth Analg. 2003 Aug;97(2):534–40, table of contents. PubMed PMID: 12873949

[4] Pavlin DJ, Chen C, Penaloza DA, et al. Pain as a factor complicating recovery and discharge after ambulatory surgery. Anesth Analg. 2002 Sep;95(3):627–34, table of contents. PubMed PMID: 12198050

[5] Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron. 2000 Apr;26(1):13–25. Review. PubMed PMID: 10798838

[6] Todorovic SM, Jevtovic-Todorovic V, Meyenburg A, et al. Redox modulation of T-type calcium channels in rat peripheral nociceptors. Neuron. 2001 Jul 19;31(1):75–85. PubMed PMID:11498052

[7] Todorovic SM, Meyenburg A, Jevtovic-Todorovic V. Mechanical and thermal antinociception in rats following systemic administration of mibebradil, a T-type calcium channel blocker. Brain Res. 2002 Oct 4;951(2):336–340. PubMed PMID: 12270514

[8] Todorovic SM, Rastogi AJ, Jevtovic-Todorovic V. Potent analgesic effects of anticonvulsants on peripheral thermal nociception in rats. Br J Pharmacol. 2003 Sep;140(2):255–260. Epub 2003 Aug 4. PubMed PMID: 12970103; PubMed Central PMCID: PMC1574030.

[9] Kim D, Park D, Choi S, et al. Thalamic control of visceral nociception mediated by T-type Ca2+ channels. Science. 2003 Oct 3;302(5642):117–119. PubMed PMID: 14526084

[10] Joksimovic SL, Joksimovic SL, Tesic V, et al. Selective inhibition of CaV3.2 channels reverses hyperexcitability of peripheral nociceptors and alleviates postsurgical pain. Sci Signal. 2013 Aug 28;6(5):pii: eaao4425. . PubMed PMID: 30154101; PubMed Central PMCID: PMCID6193449.

[11] Wang YX, Pettus M, Gao D, et al. Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain. Pain. 2000 Feb;84(2–3):151–158. PubMed PMID: 10666519

[12] Field MJ, Holloman EF, McCleary S, et al. Evaluation of gabapentin and S(-)-3-isobutylgaba in a rat model of postoperative pain. J Pharmacol Exp Ther. 1997 Sep;282(3):1242–1246. PubMed PMID: 9316831

[13] Patte-Mensah C, Meyer L, Taleb O, et al. Potential role of allopregnanolone for a safe and effective therapy of neuropathic pain. Prog Neurobiol. 2014;113:70–78.

[14] Mensah-Nyagan AG, Kibaly C, Schaeffer V, et al. Endogenous steroid production in the spinal cord and potential involvement in neuropathic pain modulation. J Ster Biochem Mol Biol. 2008;109(3–5):286–293.

[15] Schumacher M, Liere P, Akwa Y, et al. Pregnenolone sulfate in the brain: a controversial neurosteroid. Neurochem Int. 2008;52(4–5):522–540.

[16] Baulieu EE. Robel P neurosteroids: a new brain function? J Ster Biochem Mol Biol. 1990;37(3):395–403.

[17] Majewska MD, Harrison NL, Schwartz RD, et al. Steroid hormone metabolites are barbiturate like modulators of the GABA receptor. Science. 1986;232:1004–1007.

[18] Coronel MF, Labombarda F, Villar MJ, et al. Progesterone Prevents Allodynia after Experimental Spinal Cord Injury. J Pain. 2011;12(1):71–83.

[19] Coronel MF, Raggio MC, Adler NS, et al. Progesterone modulates pro-inflammatory cytokine expression profile after spinal cord injury: implications for neuropathic pain. J Neuroimmun. 2016;292:85–92.

[20] Pathiratha S, Brimelow BC, Jagodic MM, et al. New evidence that both T-type calcium channels and GABAAchannels are responsible for the potent peripheral analgesic effects of 5α-reduced neuroactive steroids. Pain. 2005a;114(3):429–443.

[21] Ayoola C, Hwang SM, Hong SJ, et al. Inhibition of CaV3.2 T-type calcium channels in peripheral sensory neurons contributes to analgesic properties of epipregnanolone. Psychopharmacol. 2014;231(17):3503–3515.

[22] Todorovic SM, Pathiratha S, Brimelow BC, et al. 5β - reduced neuroactive steroids are novel voltage-dependent blockers of T-Type Ca2+ channels in rat sensory neurons in vitro and potent peripheral analgesics in vivo. Mol Pharmacol. 2004;66(5):1223–1235.

[23] Brennan TJ, Vandermeulen EP, Gebhart G F. Characterization of a rat model of incisional. Pain. 1996;64(3):493–501.

[24] Bogatzki-Zahn EM, Segelcke D, Schug SA. Posto perative pain-from mechanisms to treatment. Pain Rep. 2017;2(2):e588.

[25] Wozniak DF, Olney JW, Kettinger LIII. Price M and Miller JP. Behavioral effects of MK-801 in the rat. Psychopharmacol. 1999;101:47–56.

[26] Bannister RA, Melliti K, Adams BA. Differential modulation of CaV2.3 Ca2+ channels by Galphq/11-coupled muscarinic receptors. Mol Pharmacol. 2004;65(2):381–388.

[27] Scroggs RS, Fox AP. Calcium current variation between acutely isolated adult rat dorsal root ganglion neurons of different size. J Physiol. 1992 Jan;445:639–658. PubMed PMID: 1323671; PubMed Central PMCID: PMC1180002

[28] Mintz IM, Venema VJ, Swiderek KM, et al. P-type calcium channels blocked by the spider toxin
[43] Rusin KI, Moises HC. mu-Opioid receptor activation reduces multiple components of high-threshold calcium current in rat sensory neurons. J Neurosci. 1995 Jun;15(6):4315–4327. PubMed PMID: 7540671

[34] Holz GG 4th, Rane SG, Dunlap K. GTP-binding proteins mediate transmitter inhibition of voltage-dependent calcium channels. Nature (Lond). 1986;329:670–672.

[35] Mensah-Nyagan G, Do-Rego JL, Beauean D, et al. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol Rev. 1999;51(1):63–81.

[36] Mensah-Nyagan AG, Meyer L, Schaeffer V, et al. Evidence for a key role of steroids in the modulation of pain. Psychoneuroendocrinology. 2009 Dec;34(Suppl 1): S169–1677. Review. PubMed PMID:19577851. DOI:10.1016/j.psyneuen.2009.06.004.

[37] Leonelli E, Bianchi R, Cavaletti G, et al. Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. Neuroscience. 2007;144(4):1293–1304.

[38] Meyer L, Patte-Mensah C, Taleb O, et al. Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy. Cell Mol Life Sci. 2010;67:3017–3034.

[39] Meyer L, Patte-Mensah C, Taleb O, et al. Allopregnanolone prevents and suppresses oxaliplatin-evoked painful neuropathy: multiparametric assessment and direct evidence. Pain. 2011;152:170–181.

[40] Ocivrik R, Pearson MBE, Franklin KBJ, et al. Antinociceptive profile of ring a-reduced progesterone metabolites in the formalin test. Pain. 2008;138 (2):402–409.

[41] Pathiratna S, Todorovic SM, Covey DF, et al. 5α-Reduced neuroactive steroids alleviate thermal and mechanical hyperalgesia in rats with neuropathic pain. Pain. 2005b;117(3):326–339.

[42] Bennett G, Serafini M, Burchiel K, et al. Evidence-based review of the literature on intrathecal delivery of pain medication. J Pain Symp Manag. 2000;20(2):12–36.

[43] Zahn PK, Brennan TJ. Lack of effect of intrathecally administered Nmethyl-D-aspartate receptor antagonists in a rat model for postoperative pain. Anesthesiology. 1998;88:143±156.

[44] Zahn PK, Umali E, Brennan TJ. Intrathecal non-NMDA excitatory amino acid receptor antagonists inhibit pain behaviors in a rat model of postoperative pain. Pain. 1998;74:213±223.

[45] Zahn PK, Gyysbers D, Brennan TJ. Effect of systemic and intrathecal morphine in a rat model of postoperative pain. Anesthesiology. 1997;86:1066±1077.

[46] Zamponi GW, Lewis RJ, Todorovic SM, et al. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Rev. 2009 Apr;60(1): 84–89. . Epub 2008 Dec 31. Review.

[47] Todorovic SM, Jevtovic-Todorovic V. T-type voltage-gated calcium channels as targets for the development of novel pain therapies. Br J Pharmacol. 2011 Jun;163(3):484–495. . Review. PubMed PMID:21306582; PubMed Central

[48] Rose KE, Lunardi N, Boscolo A, et al. Immunohistological demonstration of Cav3.2 T-type voltage-gated calcium channel expression in soma of dorsal root ganglion neurons and peripheral axons of rat and mouse. Neuroscience. 2013;250:263–274.

[49] Bourinet E, Allou A, Monteil A, et al. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. Embo J. 2005;24(2):315–324.

[50] Jacus MO, Uebele VN, Renger JJ, et al. Presynaptic Cav3.2 channels regulate excitatory neurotransmission in nociceptivedorsal horn neurons. J Neurosci. 2012;32: 9374–9382.

[51] Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001;413:203–2109.

[52] Catterall WA. Biochemical studies of Ca2 channels. In: voltagegated calcium. Zamponi G, ed. New York, NY: Landes Bioscience; 2005. p. 48–60.

[53] Smith MT, Cabot PJ, Ross FB, et al. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinoiception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain. 2002;96:119–127.

[54] François-Moutal L, Wang Y, Moutal A, et al. A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits Cav2.2 trafficking and reverses inflammatory and postoperative pain behaviors. Pain. 2015 Jul;156(7):1247–1264. PubMed PMID: 25782368; PubMed Central PMCID: PMC5766324

[55] Saegusa H, Kurihara T, Zong S, et al. Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. EMBO J. 2001 May 15;20(10):2349–2356. PubMed PMID:11350923; PubMed Central PMCID: PMC125247.

[56] Hatakeyama S, Wakamori M, Ito M, et al. Differential nociceptive responses in mice lacking the alpha(1B) subunit ofN-type Ca2+(+) channels. Neuroreport. 2001 Aug 8;12(11):2423–2427. PubMed PMID:11496122.

[57] Atanassoff PG, Hartmannsgruber MW, Thrasher J, et al. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med. 2000 May-Jun;25 (3):274–278. PubMed PMID: 10834782.

[58] Fritch-Mullen JM, Spence KT. Neurosteroids block Ca2+ channel current in freshly isolated hippocampal CA1 neurons. Eur J Pharmacol. 1991 Sep 17;202 (2):269–272. PubMed PMID: 1666369

[59] Nakashima YM, Todorovic SM, Covey DF, et al. The anesthetic steroid (+)-3alpha-hydroxy-Salphandrostane-17beta-carbonitrile blocks N-, Q-, and R-type, but not L- and P-type, high voltage-activated Ca2+ current in hippocampal and dorsal root ganglion...
neurons of the rat. Mol Pharmacol. 1998 Sep;54(3):559–568. PubMed PMID: 9730915

[60] Raingo J, Castiglioni AJ, Lipscombe D. Alternative splicing controls G protein-dependent inhibition of N-type calcium channels in nociceptors. Nat Neurosci. 2007;10:285–292.

[61] Zamponi GW, Bourinet E, Nelson D, et al. Crosstalk between G proteins and protein kinase C mediated by the calcium channel alpha1 subunit. Nature. 1997 Jan 30;385(6615):442–446. PubMed PMID: 9009192

[62] Swartz KJ. Modulation of Ca2+ channels by protein kinase C in rat central and peripheral neurons: disruption of G protein-mediated inhibition. Neuron. 1993 Aug;11(2):305–320. PubMed PMID: 8102534

[63] Doğrul A, Yeşilyurt O, Işimer A, et al. L-type and T-type calcium channel blockade potentiate the analgesic effects of morphine and selective mu opioid agonist, but not to selective delta and kappa agonist at the level of the spinal cord in mice. Pain. 2001 Jul;93(1):61–68. PubMed PMID: 11406339

[64] Shimizu N, Kishioka S, Maeda T, et al. Role of pharmaco-kinetic effects in the potentiation of morphine analgesia by L-type calcium channel blockers in mice. J Pharmacol Sci. 2004;94:240–245.

[65] Todorovic SM, Pathirathna S, Meyenburg A, et al. Mechanical and thermal anti-nociception in rats after systemic administration of verapamil. Neurosci Lett. 2004 Apr 22;360(1–2):57–60. PubMed PMID: 15082178

[66] Benedek G, Szikszay M. Potentiation of thermoregulatory and analgesic effects of morphine by calcium antagonists. Pharmacol Res Commun. 1984 Oct;16(10):1009–1018. PubMed PMID: 6504960

[67] Contreras E, Tamayo L, Amigo M. Calcium channel antagonists increase morphine-induced analgesia and antagonize morphine tolerance. Eur J Pharmacol. 1988 Apr 13;148(3):463–466. PubMed PMID: 3384008

[68] Omote K, Sonoda H, Kawamata M, et al. Potentiation of antinociceptive effects of morphine by calcium-channel blockers at the level of the spinal cord. Anesthesiology. 1993 Oct;79(4):746–752. PubMed PMID: 8214754